
Neuronetics Inc (STIM) Stock Forecast & Price Target
Neuronetics Inc (STIM) Analyst Ratings
Bulls say
Neuronetics is expected to have a strong revenue growth in the coming years due to their expansion into the fast-growing psychedelic therapy market and their effective treatment device, NeuroStar. Despite facing challenges, the company has implemented measures to improve operations and has acquired Greenbrook TMS to enhance their capabilities. With projected revenue of $161M in 2026, the company has potential for growth and is a strong competitor in the market against companies like BrainsWay and COMPASS Pathways.
Bears say
Neuronetics is facing significant obstacles in their transition to becoming a key player in interventional psychiatry, including difficulties in scalability and awareness among providers about their non-invasive alternative treatment option. Additionally, their reliance on a treatment session model has limited their reach and profitability, and they may need to raise additional capital in the near term. While they have a large market opportunity, their operating losses are expected to continue and there are risks associated with competition and alternative therapies.
This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.
Neuronetics Inc (STIM) Analyst Forecast & Price Prediction
Start investing in Neuronetics Inc (STIM)
Order type
Buy in
Order amount
Est. shares
0 shares